Mayinglong Pharmaceutical Group Co Ltd (600993) - Total Assets
Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) holds total assets worth CN¥5.64 Billion CNY (≈ $825.21 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 600993 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Mayinglong Pharmaceutical Group Co Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore Mayinglong Pharmaceutical Group Co Ltd (600993) long-term investment share to see how much of total assets are deployed in long-term investments.
Mayinglong Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Mayinglong Pharmaceutical Group Co Ltd's total assets of CN¥5.64 Billion consist of 70.0% current assets and 30.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 38.4% |
| Accounts Receivable | CN¥290.99 Million | 5.4% |
| Inventory | CN¥320.87 Million | 5.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥229.40 Million | 4.2% |
| Goodwill | CN¥22.99 Million | 0.4% |
Asset Composition Trend (2001–2025)
This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mayinglong Pharmaceutical Group Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mayinglong Pharmaceutical Group Co Ltd's current assets represent 70.0% of total assets in 2025, an increase from 57.5% in 2001.
- Cash Position: Cash and equivalents constituted 38.4% of total assets in 2025, up from 31.1% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 5.9% of total assets.
Mayinglong Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Mayinglong Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Mayinglong Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.06 | 4.60 | 4.15 |
| Quick Ratio | 4.71 | 4.29 | 3.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.05 Billion | CN¥3.11 Billion | CN¥2.52 Billion |
Mayinglong Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Mayinglong Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | CN¥5.44 Billion |
| Market Capitalization | $1.42 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Mayinglong Pharmaceutical Group Co Ltd's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Mayinglong Pharmaceutical Group Co Ltd's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual total assets of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.44 Billion ≈ $795.49 Million |
+4.91% |
| 2024-12-31 | CN¥5.18 Billion ≈ $758.28 Million |
+7.30% |
| 2023-12-31 | CN¥4.83 Billion ≈ $706.71 Million |
-4.51% |
| 2022-12-31 | CN¥5.06 Billion ≈ $740.09 Million |
+22.55% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.90 Million |
+6.74% |
| 2020-12-31 | CN¥3.87 Billion ≈ $565.78 Million |
+17.68% |
| 2019-12-31 | CN¥3.29 Billion ≈ $480.76 Million |
+12.26% |
| 2018-12-31 | CN¥2.93 Billion ≈ $428.24 Million |
+6.27% |
| 2017-12-31 | CN¥2.75 Billion ≈ $402.99 Million |
+10.30% |
| 2016-12-31 | CN¥2.50 Billion ≈ $365.35 Million |
+3.60% |
| 2015-12-31 | CN¥2.41 Billion ≈ $352.64 Million |
+10.26% |
| 2014-12-31 | CN¥2.19 Billion ≈ $319.83 Million |
+7.80% |
| 2013-12-31 | CN¥2.03 Billion ≈ $296.68 Million |
+10.02% |
| 2012-12-31 | CN¥1.84 Billion ≈ $269.67 Million |
+11.18% |
| 2011-12-31 | CN¥1.66 Billion ≈ $242.56 Million |
+14.40% |
| 2010-12-31 | CN¥1.45 Billion ≈ $212.02 Million |
+0.91% |
| 2009-12-31 | CN¥1.44 Billion ≈ $210.11 Million |
+23.47% |
| 2008-12-31 | CN¥1.16 Billion ≈ $170.17 Million |
+6.53% |
| 2007-12-31 | CN¥1.09 Billion ≈ $159.74 Million |
-1.27% |
| 2006-12-31 | CN¥1.11 Billion ≈ $161.80 Million |
+43.23% |
| 2005-12-31 | CN¥772.00 Million ≈ $112.97 Million |
+13.04% |
| 2004-12-31 | CN¥682.94 Million ≈ $99.94 Million |
+85.61% |
| 2003-12-31 | CN¥367.95 Million ≈ $53.84 Million |
+1.33% |
| 2002-12-31 | CN¥363.13 Million ≈ $53.14 Million |
+13.16% |
| 2001-12-31 | CN¥320.89 Million ≈ $46.96 Million |
-- |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers… Read more